DrugPatentWatch Database Preview

Details for Patent: 8,088,934

« Back to Dashboard

Which drugs does patent 8,088,934 protect, and when does it expire?

Patent 8,088,934 protects AMITIZA and is included in one NDA.

This patent has forty-five patent family members in twenty-four countries.

Summary for Patent: 8,088,934

Title:	Composition and method for stabilizing the same
Abstract:	Disclosed is a novel composition comprising a novel bi-cyclic compound, which is expected to be pharmaceutically active, and a glyceride. The stability of the bi-cyclic compound can be improved significantly by dissolving the same in a glyceride.
Inventor(s):	Ueno; Ryuji (Montgomery, MD), Habe; Tsuyoshi (Sasayama, JP)
Assignee:	SUCAMPO AG (Zurich, CH)
Application Number:	12/144,000
Patent Claim Types: see list of patent claims	Compound;

Drugs Protected by US Patent 8,088,934

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Patented / Exclusive Use	Submissiondate
Sucampo Pharma Llc	AMITIZA	lubiprostone	CAPSULE;ORAL	021908-002	Apr 29, 2008		RX	Yes	No				Y
Sucampo Pharma Llc	AMITIZA	lubiprostone	CAPSULE;ORAL	021908-001	Jan 31, 2006		RX	Yes	Yes				Y

International Family Members for US Patent 8,088,934

Country	Patent Number	Estimated Expiration	Supplementary Protection Certificate	SPC Country	SPC Expiration
Argentina	026046
Argentina	089848
Argentina	109354
Austria	267189